Both Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) are each other’s competitor in the Biotechnology industry. Thus the compare of their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Portola Pharmaceuticals Inc.||40.13M||62.73||350.22M||-5.38||0.00|
|OncoMed Pharmaceuticals Inc.||44.42M||0.94||8.10M||0.13||6.31|
Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Portola Pharmaceuticals Inc. and OncoMed Pharmaceuticals Inc.
Table 2 shows the net margins, return on assets and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Portola Pharmaceuticals Inc.||-872.71%||-136.3%||-69.7%|
|OncoMed Pharmaceuticals Inc.||-18.24%||25.8%||6.5%|
Volatility & Risk
A 2.38 beta means Portola Pharmaceuticals Inc.’s volatility is 138.00% more than S&P 500’s volatility. Competitively, OncoMed Pharmaceuticals Inc. is 79.00% more volatile than S&P 500, because of the 1.79 beta.
Portola Pharmaceuticals Inc.’s Current Ratio is 6.6 while its Quick Ratio is 6.5. On the competitive side is, OncoMed Pharmaceuticals Inc. which has a 3.4 Current Ratio and a 3.4 Quick Ratio. Portola Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to OncoMed Pharmaceuticals Inc.
Portola Pharmaceuticals Inc. and OncoMed Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Portola Pharmaceuticals Inc.||0||1||3||2.75|
|OncoMed Pharmaceuticals Inc.||0||1||0||2.00|
$40.5 is Portola Pharmaceuticals Inc.’s average price target while its potential upside is 7.51%. OncoMed Pharmaceuticals Inc. on the other hand boasts of a $1.5 average price target and a 38.89% potential upside. Based on the analysts opinion we can conclude, OncoMed Pharmaceuticals Inc. is looking more favorable than Portola Pharmaceuticals Inc.
Institutional & Insider Ownership
Roughly 0% of Portola Pharmaceuticals Inc. shares are owned by institutional investors while 61% of OncoMed Pharmaceuticals Inc. are owned by institutional investors. Insiders owned roughly 1.1% of Portola Pharmaceuticals Inc.’s shares. Comparatively, OncoMed Pharmaceuticals Inc. has 0.7% of it’s share owned by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Portola Pharmaceuticals Inc.||7.31%||22.95%||59.12%||15.13%||5.58%||70.7%|
|OncoMed Pharmaceuticals Inc.||-3.83%||7.72%||-34.35%||-65.67%||-66.23%||9.81%|
For the past year Portola Pharmaceuticals Inc. was more bullish than OncoMed Pharmaceuticals Inc.
On 9 of the 13 factors OncoMed Pharmaceuticals Inc. beats Portola Pharmaceuticals Inc.
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.
OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand. The company has strategic alliances with GlaxoSmithKline LLC to develop and commercialize antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.